Is CYP2C19 genotype-guided de-escalation feasible and efficient in an all-comers ACS population?
All-comers acute coronary syndrome (ACS) population
CYP2C19 genotype-guided de-escalation using point-of-care (POC) genotyping
Feasibility, turnaround times, time to de-escalation, and physician adherence to genotype results
Point-of-care CYP2C19 genotyping is a feasible and efficient strategy for guiding rapid de-escalation of antiplatelet therapy from ticagrelor to clopidogrel in patients with acute coronary syndrome.
CYP2C19 genotype-guided-de-escalation in an all-comers ACS population is feasible. POC genotyping leads to shorter turnaround times and quicker de-escalation. Time to de-escalation from ticagrelor to clopidogrel in noncarriers was short, with high physician adherence to genotype results.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jaouad Azzahhafi
Interventional Cardiology
Wout W. A. van den Broek
Interventional Cardiology
Dean R.P.P. Chan Pin Yin
Interventional Cardiology
Journal of Cardiovascular Pharmacology and Therapeutics
SHILAP Revista de lepidopterología
Erasmus MC
St. Antonius Ziekenhuis
Building similarity graph...
Analyzing shared references across papers
Loading...
Azzahhafi et al. (Sun,) studied this question.
synapsesocial.com/papers/69a31653a60bae612d55e494 — DOI: https://doi.org/10.1177/10742484231210704